Clinical trials: Chronic Kidney Disease - Stage V
Hyperphosphatemia, Kidney Disease
Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients
Patients with end-stage renal disease (ESRD) commonly develop hyperphosphatemia due to the loss of excretory function of the kidney.
- Trial name
- NCT00660530
- Testing
- Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Illinois Chicago
Chronic Kidney Disease Stage 5 (Dialysis Dependent)
A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D
The purpose of this study is to compare the efficacy and safety of intravenous iron isomaltoside 1000 with intravenous iron sucrose in patients suffering from Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D).
- Trial name
- NCT01222884
- Testing
- Monofer, Iron sucrose
- Where
- India
- Volunteers
- 351 people
- Sponsor
- Pharmacosmos A/S
Chronic Kidney Failure, Chronic Kidney Disease stage3
Pathophysiological Characterization of the Neuromuscular Function of a Population With Multiple Comorbidities Suffering From Chronic Renal Failure in Pre-dialysis.
The evolution of chronic kidney disease (CKD) causes a systemic upheaval on the body and a deep fatigue is very often described by patients (50-70% of the patients) even before the start of dialysis (pre-dialysis).
- Conditions
- Chronic Kidney Failure, Chronic Kidney Disease stage3, Chronic Kidney Disease, Stage 4 (Severe), Chronic Kidney Disease Stage 5
- Trial name
- PIONNIER (NCT03998917)
- Testing
- Discrimination of neuromuscular alterations protocol
- Where
- France
- Volunteers
- healthy volunteers welcome
- Sponsor
- Centre Hospitalier le Mans
Focal Segmental Glomerulosclerosis
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5
This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with…
- Trial name
- NCT00816504
- Testing
- Galactose
- Where
- United States
- Sponsor
- Northwell Health
Stage 5 Chronic Kidney Disease, Hemodialysis
Comparison of Outcomes Between Hemodialysis and Peritoneal Dialysis Patients in a Multi-Ethnic Asian Population
End-stage renal disease (ESRD) presents a heavy burden on a patient's psychological and social life, as well as overall quality of life (QoL).
- Conditions
- Stage 5 Chronic Kidney Disease, Hemodialysis, Peritoneal Dialysis
- Trial name
- NCT01587443
- Where
- Singapore
- Volunteers
- 200 people
- Sponsor
- National University of Singapore
Kidney Disease, Chronc Kidney Disease Stage 5
The Effect of Patient Empowerment Learning (With AI) About Itching in Hemodylasis Patients.
This study investigates whether artificial intelligence-supported patient education can reduce itching and improve patient empowerment in individuals with chronic kidney disease undergoing hemodialysis.
- Conditions
- Kidney Disease, Chronc Kidney Disease Stage 5, Chronic Kidney Disease
- Trial name
- NCT07740083
- Testing
- Artificial Intelligence-Supported Patient Education
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people
- Sponsor
- Izmir Tinaztepe University
Chronic Kidney Disease Stage 5 on Dialysis
Desidustat in the Treatment of Anemia in CKD on Dialysis Patients
A phase 3, multicenter, open-label, randomized, active-controlled study to evaluate the efficacy and safety of Desidustat Tablet versus Epoetin alfa Injection for the treatment of anemia in patients with CKD on dialysis. (DREAM-D)
- Trial name
- DREAM-D (NCT04215120)
- Testing
- Desidustat Oral Tablet, Epoetin Alfa
- Where
- 7 sites in India
- Volunteers
- 392 people
- Sponsor
- Zydus Lifesciences Limited
Hypercholesterolemia, CKD Stage 5
Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia
Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol, reducing in turn the risk of cardiovascular events.
- Conditions
- Hypercholesterolemia, CKD Stage 5, Chronic Kidney Disease Requiring Chronic Dialysis
- Trial name
- NCT04659525
- Testing
- Evolocumab, Ezetimibe
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Policlinico Casilino ASL RMB
Chronic Renal Insufficiency
Very Low Protein Diet and Renal Death in Chronic Kidney Disease (CKD)-ERIKA Study
The purpose of this study is to determine whether the use of a very low protein diet is effective in delaying the start of chronic dialysis treatment in patients affected by chronic kidney disease (CKD).
- Trial name
- NCT00323713
- Testing
- Very low protein diet, Low protein diet
- Where
- 17 sites in Italy
- Volunteers
- 360 people
- Sponsor
- Azienda Sanitaria ASL Avellino 2
ESRD, CKD Stage 4, CKD Stage 5
Canagliflozin in Advanced Renal Disease With MRI Endpoints
This is a phase II, proof of concept, placebo-controlled, randomized clinical trial, assessing the effect of canagliflozin on cardiac structure and function in patients with advanced renal disease, including those on maintenance…
- Trial name
- CARe-MRI (NCT06182839)
- Testing
- Canagliflozin 300Mg Tab
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
End-Stage Renal Disease, Secondary Hyperparathyroidism
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
The objective is to evaluate the safety of paricalcitol capsules in pediatric subjects, ages 10 to 16 years old, with Stage 5 chronic kidney disease (kidney failure) receiving peritoneal dialysis or hemodialysis and being treated…
- Trial name
- NCT01382212
- Testing
- paricalcitol
- Volunteers
- 13 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease
The Use of Low Molecular Weight Heparin in Hemodiafiltration
Low molecular weight heparin (LMWH) is injected in the dialysis circuit at the start of the session. In the present study we compare 3 different methods of injection of LMWH: parameters of dialysis efficiency and clotting are…
- Trial name
- NCT00756145
- Testing
- At start of the session, at the inlet line, 5 minutes after the start of the session, at the inlet line, At the start of the session, at the outlet line
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- University Hospital, Ghent
Fractures, Bone, CKD Stage 4
The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients.
the risk of bleeding may be greater than the benefit of antithrombotic protection when prophylactically anticoagulating a patient with a lower limb fracture and advanced CKD.
- Conditions
- Fractures, Bone, CKD Stage 4, CKD Stage 3, CKD Stage 5
- Trial name
- FAA (NCT06795698)
- Testing
- Enoxaparin
- Where
- Mexico
- Volunteers
- 61 people
- Sponsor
- Hospital Civil de Guadalajara
End-Stage Kidney Disease
Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis
To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to…
- Trial name
- NCT00062699
- Testing
- Zemplar (paricalcitol injection), Calcijex
- Where
- 60 sites in United States
- Volunteers
- 2,200 people
- Sponsor
- Abbott
Chronic Kidney Disease
Paricalcitol Injection Phase II Trial
The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal…
- Trial name
- NCT00646932
- Testing
- paricalcitol
- Where
- 10 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Abbott
COVID-19, Chronic Kidney Disease stage4
Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir
Nirmatrelvir-ritonavir is approved for coronavirus disease 2019 (COVID-19) but not initially recommended in patients with severe renal impairment.
- Conditions
- COVID-19, Chronic Kidney Disease stage4, Chronc Kidney Disease Stage 5
- Trial name
- NCT05624840
- Testing
- Nirmatrelvir/ritonavir
- Where
- Hong Kong
- Volunteers
- 85 people
- Sponsor
- Chinese University of Hong Kong
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis
To evaluate the efficacy of fasiglifam 50 mg once daily compared to placebo on glycemic control as measured by glycosilated haemoglobin (HbA1c) over a 16-week treatment period in participants with Type 2 Diabetes Mellitus (T2DM)…
- Trial name
- NCT02015780
- Testing
- Fasiglifam, Antihyperglycemic therapy
- Where
- 30 sites in United States, Bulgaria and 5 more
- Sponsor
- Takeda
Chronic Kidney Disease Stage 5, Peritoneal Dialysis Complication
Utility of Telemedicine in the Follow-Up of Patients in Peritoneal Dialysis
Peritoneal dialysis (PD) technology is available but has not been tested in the real world. Therefore, the aim of this study is to test the utility of telemedicine in reducing mortality, hospitalizations, unscheduled visits, and…
- Trial name
- NCT04034966
- Testing
- Claria telemedicine device
- Where
- Mexico
- Volunteers
- 750 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), CKD Stage 3
Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease
In this pilot clinical trial, the investigators will recruit and randomize 120 patients with diabetes mellitus and chronic kidney disease (CKD/DM) stages 3 to 5 to a patient-centered and flexible Plant-Focused Nutrition in…
- Conditions
- Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), CKD Stage 3, CKD Stage 4, CKD Stage 5
- Trial name
- PLAFOND (NCT05514184)
- Testing
- PLAFOND diet
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of California, Irvine
Kidney Failure, Chronic
Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis
To show non-inferiority in the incidence rates of elevated calcium-phosphorus product between two treatment groups: 1) a group having an initial dose based on baseline PTH (baseline iPTH/80) and 2) a group having a starting dose…
- Trial name
- NCT00091481
- Testing
- Zemplar
- Where
- 19 sites in Greece
- Volunteers
- 201 people
- Sponsor
- Abbott